研究概要
我们的发现揭示了一种新的免疫代谢机制,即肿瘤来源的ORM2促进CRC中的免疫逃逸和肝转移。靶向ORM2–ACVR1轴可能为CRLM提供一种有前景的治疗策略。
研究思路结论见上方概要
背景
肝脏是结直肠癌(CRC)最常见的远处转移部位,而肝转移(LM)仍是CRC相关死亡的主要原因。免疫微环境在调控LM进展中发挥关键作用,但参与其重塑的关键分子驱动因素仍知之甚少。
方法
我们在结直肠癌肝转移(CRLM)小鼠模型中进行了体内CRISPR-Cas9筛选,以鉴定转移定植的关键调控因子。通过体外和体内功能研究,评估了ORM2在调控CRLM中的作用及机制。
结果
我们确定 orosomucoid 2 (ORM2) 是一个主要候选因子,其敲除显著抑制了 CRLM。在临床上,ORM2 表达在 CRLM 组织中显著上调,并与患者不良预后相关。ORM2 的基因消融显著减少了体内 LM。在机制上,ORM2 的促转移作用依赖于自然杀伤 (NK) 细胞。进一步分析显示,ORM2 与 activin A receptor type 1 (ACVR1) 相互作用以激活 Hippo 信号通路,从而导致丝氨酸和一碳代谢受到抑制,而这是 NK 细胞细胞毒性功能的关键通路。
展开英文摘要原文
BACKGROUND: The liver is the most common site of distant metastasis in colorectal cancer (CRC), and liver metastasis (LM) remains the leading cause of CRC-related mortality. The immune microenvironment plays a crucial role in regulating LM progression, but the key molecular drivers involved in its remodeling remain poorly understood. METHODS: We performed an in vivo CRISPR-Cas9 screen in a murine model of colorectal cancer liver metastasis (CRLM) to identify key regulators of metastatic colonization. In vitro and in vivo functional studies were conducted to evaluate the role and mechanisms of ORM2 in modulating CRLM. RESULTS: We identified orosomucoid 2 (ORM2) as a top candidate whose knockout markedly suppressed CRLM. Clinically, ORM2 expression was significantly upregulated in CRLM tissues and correlated with poor patient prognosis. Genetic ablation of ORM2 significantly reduced LM in vivo. Mechanistically, the pro-metastatic role of ORM2 was dependent on natural killer (NK) cells. Further analyses revealed that ORM2 interacts with activin A receptor type 1 (ACVR1) to activate the Hippo signaling pathway, leading to the suppression of serine and one-carbon metabolism, a key pathway for NK cell cytotoxic function. CONCLUSIONS: Our findings uncover a novel immunometabolic mechanism by which tumor-derived ORM2 promotes immune evasion and liver metastasis in CRC. Targeting the ORM2–ACVR1 axis may offer a promising therapeutic strategy for CRLM.
论文信息
- 作者
- Zhou J、He X、Xiang Z、Wang M、Xu W、Wang Y、Chen Y、Zhang T
- 第一作者单位
- Department of Hepatic Surgery, Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.China
- 通讯作者单位
- Department of Hepatic Surgery, Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China. 13020143060@163.com.China
- 期刊
- Molecular cancer2026 Mar 3